RxDoctor Payments Data

Kacey Gilford, OD

Optometrist · Phoenix, AZNPI 1245510379

Payments from drug & device makers

$2,828in general payments, 2019–2025

Across 84 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$507
  • Alcon$407
  • Novartis$339
  • Glaukos Corporation$252
  • Sun Pharmaceutical Industries Inc.$249
  • Apellis Pharmaceuticals, Inc.$230
  • plus $843 from 9 others

What the payments were for

  • Food & beverage$2,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,828 in reported general payments places this provider in the 85th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$182,450
Medicare patients
695
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost80$61,942
XiidraLifitegrast35$50,246
RestasisCyclosporine27$35,519
Latanoprost1,150$13,738
Fluorometholone141$8,564
CombiganBrimonidine Tartrate/Timolol12$5,153
Prednisolone Acetate130$4,393
Brimonidine Tartrate199$1,995
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat116$1,696
Timolol Maleate151$1,556
Dorzolamide Hcl55$1,236
ErythromycinErythromycin Base63$857
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha40$503
Ofloxacin14$205
Diclofenac Sodium11$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan$78$61,94280 claims
Bausch & Lomb Americas Inc.Xiidra$142$50,24635 claims
AbbVieRestasis, Combigan$204$40,67239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →